Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.
Open Access
- 1 July 1998
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 134 (7), 805-809
- https://doi.org/10.1001/archderm.134.7.805
Abstract
ATOPIC DERMATITIS (AD) is one of the most common skin diseases, with a complex genetic background,1 a lifetime prevalence of up to 20%,2,3 and an increasing number of cases.4-6 Although there are other treatments (emollients, phototherapy, elimination of exacerbating factors, psychotherapy, and patient education), the number of medications for treating this chronic disease is limited: tar preparations, topical corticosteroids (low, medium, and high potency), antiseptics, antibiotics, cyclosporine, and antihistamines.7 Most treatments may be used only for a limited period or are less effective in the long term (tachyphylaxis8). The development of new compounds is mandatory for treatment of this persistent disease.Keywords
This publication has 8 references indexed in Scilit:
- A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases:in vivopharmacologyBritish Journal of Dermatology, 1997
- A Short-Term Trial of Tacrolimus Ointment for Atopic DermatitisNew England Journal of Medicine, 1997
- Tacrolimus concentrations in blood during topical treatment of atopic dermatitisThe Lancet, 1996
- Search for genes predisposing to atopic diseasesThe Lancet, 1996
- Tacrolimus ointment for atopic dermatitisThe Lancet, 1994
- The prevalence of childhood atopic eczema in a general populationJournal of the American Academy of Dermatology, 1994
- Is the prevalence of atopic dermatitis increasing?Clinical and Experimental Dermatology, 1992
- Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitisThe Lancet, 1991